Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Sue-zette Valera"'
Autor:
Sunil Sharma, Petronella O. Witteveen, Martijn P. Lolkema, Dagmar Hess, Hans Gelderblom, Syed A. Hussain, Maria G. Porro, Edward Waldron, Sue-zette Valera, Song Mu
Publikováno v:
Cancer Chemotherapy and Pharmacology, 75(1), 87. Springer Verlag
Cancer Chemotherapy and Pharmacology, 75(1), 87-95
Cancer Chemotherapy and Pharmacology, 75(1), 87-95
Purpose This study assessed the pharmacokinetics and safety of oral panobinostat and its metabolite BJB432 in patients with advanced solid tumors and normal to severely impaired renal function. Methods Patients with varying degrees of renal impairmen
Autor:
Marije Slingerland, Per Sandström, Edward Waldron, Sally Clive, Hans Gelderblom, Song Mu, Niklas Loman, Maria Grazia Porro, Sunil Sharma, Sue Zette Valera, Dagmar Hess
Publikováno v:
Cancer Chemotherapy and Pharmacology, 74(5), 1089-1098
To evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of hepatic function. Patients with advanced solid malignancies, acceptable bone marrow and renal function, and normal or impai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c14467a4e6be3f1c9e4dafd4c40fea7
https://hdl.handle.net/1887/104644
https://hdl.handle.net/1887/104644
Autor:
Madan G. Kundu, Jennifer A. Chan, Edward M. Wolin, Mike Hu, Jonathan R. Strosberg, Sue-zette Valera, Christelle Darstein, James C. Yao, Alain C. Mita, Peter Unge
Publikováno v:
Journal of Clinical Oncology. 34:4095-4095
4095Background: Pasireotide, a novel somatostatin analog, has been previously investigated but the maximum tolerated dose (MTD) has not been determined in pts with advanced NET. We report results o...
Autor:
Sue-zette Valera, Jorge Sierra, Florence Binlich, Stephen A. Strickland, Daniel J. DeAngelo, Richard F. Schlenk, Christoph Röllig, Tuli De, Bruno C. Medeiros, Robert K. Stuart, Antje Wegener, Enrique M. Ocio, Felicitas Thol, Song Mu, Alison R. Walker
Publikováno v:
Blood. 126:2553-2553
Background: For patients (pts) with acute myeloid leukemia (AML) with poor prognostic indicators, such as unfavorable cytogenetics or secondary AML, overall and event-free survival (EFS) rates are much worse, highlighting the critical need for more e
Autor:
Neeraj Agarwal, Jason Li, Nicole Hagner, Margaret M. Woo, Martijn P. Lolkema, Sunil Sharma, Emile E. Voest, Petronella O. Witteveen, Maria Grazia Porro, Dagmar Hess, Derek Mires, Sue-zette Valera
Publikováno v:
Blood. 118:5001-5001
Abstract 5001 Panobinostat is a potent class I/II/IV oral pan-deacetylase inhibitor which has shown promising clinical activity in patients with multiple myeloma and myelofibrosis, some with compromised renal and hepatic functions. The metabolism med